Arginine supplementation to improve efficiency in gas fermenting acetogens
AssigneeLanzatech New Zealand Limited
InventorsKaspar Valgepea, Michael Koepke, James Bruce Yarnton Haycock Behrendorff, Esteban Marcellin, Lars K. Nielsen, Renato de S.P. Lemgruber
Life of this patent
Estimating the term…
Abstract
The invention provides methods for improving efficiency of fermentation by arginine supplementation, and genetically modified bacterium for use therefor. More particularly the invention provides methods for (i) increasing the production ATP intensive products with arginine supplementation, (ii) increasing utilization of arginine by a C1-fixing bacterium; and (iii) providing C1-fixing bacterium with optimized arginine de-aminase pathways.
Claims20
A method for increasing the production of at least one ATP-intensive product, the method comprising;
- a. flowing a gaseous C1-containing substrate to a bioreactor containing a culture of a C1-fixing microorganism in a liquid nutrient media;
- and
- b. fermenting the culture to produce at least one product;
- wherein arginine is provided to the culture in excess of the cellular requirement of the culture;
- and wherein the C1-fixing microorganism comprises an arginine metabolism pathway.
A genetically engineered C1-fixing microorganism comprising an optimized arginine deiminase pathway.
A method for improving efficiency of arginine co-utilization with one or more gaseous substrates selected from the group consisting of CO, H2 and CO2, the method comprising culturing a genetically engineered C1-fixing bacterium comprising one or more genetic modifications selected from the group consisting of:
- i. a disruptive mutation in an arginine transporter;
- ii. overexpression of one or more endogenous enzymes selected from the group consisting of arginine deiminase (EC 3.5.3.6), ornithine carbomyltransferase (putrescine carbomyltransferase) (EC 2.1.3.3), carbamate kinase (EC 2.7.2.2), ornithine racemase (EC 5.1.1.12), ornithine aminomutase (EC 5.4.3.5), 2,4-diaminopentanoate dehydrogenase (EC 1.4.1.12), and 2-amino-4-oxopentanoate thiolase (EC 2.3.1.B10);
- iii. expression of one or more mutated endogenous enzymes selected from the group consisting of arginine deiminase (EC 3.5.3.6), ornithine carbomyltransferase (putrescine carbomyltransferase) (EC 2.1.3.3), carbamate kinase (EC 2.7.2.2), ornithine racemase (EC 5.1.1.12), ornithine aminomutase (EC 5.4.3.5), 2,4-diaminopentanoate dehydrogenase (EC 1.4.1.12), and 2-amino-4-oxopentanoate thiolase (EC 2.3.1.B10);
- and
- iv. expression of one or more exogenous enzymes selected from the group consisting of arginine deiminase (EC 3.5.3.6), ornithine carbomyltransferase (putrescine carbomyltransferase) (EC 2.1.3.3), carbamate kinase (EC 2.7.2.2), ornithine racemase (EC 5.1.1.12), ornithine aminomutase (EC 5.4.3.5), 2,4-diaminopentanoate dehydrogenase (EC 1.4.1.12), and 2-amino-4-oxopentanoate thiolase (EC 2.3.1.B10).
Dependencies are inferred from the claim text.